Abcam, ab308161, Anti-SARS-CoV-2 (COVID-19) nsp8 antibody [HL1523]

Size: 100µL
Rabbit Recombinant Monoclonal SARS-COV-2 nsp8 antibody. Carrier free. Suitable for IHC-P, WB, ICC/IF and reacts with Transfected cell line - SARS-CoV-2, Transfected cell lysate samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:HL1523,
Isotype:IgG,
Carrier free:Yes,
Reacts with:SARS-CoV-2,
Applications:WB, IHC-P, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SARS-CoV-2 nsp8 also known as non-structural protein 8 forms part of the viral replicase complex of the severe acute respiratory syndrome coronavirus 2. Nsp8 has a mass of approximately 22 kDa and plays an important role in the RNA synthesis process of the virus. It is expressed inside host cells once the virus enters the host organism. The protein functions as a part of the RNA polymerase complex working alongside other non-structural proteins to enable the virus to replicate its genetic material effectively.
Biological function summary
Nsp8 cooperates with non-structural protein 12 (nsp12) to form the RNA-dependent RNA polymerase (RdRp) complex. This complex is essential for the replication and transcription of the viral genome. Nsp8 nsp12 and nsp7 come together as a multi-protein complex enhancing the activity of the RdRp. Nsp8 has been shown to stabilize the structure and function of the replication machinery providing the necessary support for the synthesis of the viral RNA strand.
Pathways
Nsp8 plays an important role in the viral replication and transcription pathways. The polymerase activity driven by the complex of nsp8 nsp12 and nsp7 operates through the replication-transcription complex important for efficient viral propagation within the host. This process not only involves the formation of viral RNA genomes but also subgenomic RNAs which are required for viral protein translation. The interaction between these non-structural proteins ensures that the virus maintains a high level of infectious presence in its host.
Nsp8 holds a strong connection to COVID-19 the disease caused by SARS-CoV-2 infection. The interplay between nsp8 and other non-structural proteins such as nsp12 contributes directly to the ability of the virus to replicate and cause widespread infection. Inhibition of nsp8 function could provide a therapeutic target for treating COVID-19 as disruption of the RdRp complex could hinder the viral replication process. Given the pivotal role of this protein in the virus’s lifecycle targeting nsp8 could offer promising avenues for antiviral drug development.